Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).

Article  PubMed  Google Scholar 

Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15 (2020).

CAS  Google Scholar 

Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–475; discussion 475–477 (2006).

Article  PubMed  Google Scholar 

Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75–94 (2022).

Article  PubMed  Google Scholar 

Ge, P. et al. Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis. Sci. Rep. 8, 7543 (2018).

Article  PubMed  PubMed Central  Google Scholar 

D’Andrea, D. et al. The impact of primary versus secondary muscle-invasive bladder cancer at diagnosis on the response to neoadjuvant chemotherapy. Eur. Urol. Open. Sci. 41, 74–80 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Pones, M. et al. Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis. Cancers 13, 2496 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Mossanen, M. et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J. Urol. 37, 2059–2065 (2019).

Article  PubMed  Google Scholar 

Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 182, 2195–2203 (2009).

Article  PubMed  Google Scholar 

Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol. 196, 1021–1029 (2016).

Article  PubMed  Google Scholar 

Soukup, V. et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur. Urol. 72, 801–813 (2017).

Article  PubMed  Google Scholar 

Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guerin. Eur. Urol. 69, 60–69 (2016).

Article  PubMed  Google Scholar 

Rieken, M. et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol. Oncol. 36, 8.e17–8.e24 (2018).

Article  PubMed  Google Scholar 

Krajewski, W. et al. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. Urol. Oncol. 40, 491.e11–491.e19 (2022).

Article  CAS  PubMed  Google Scholar 

Lobo, N. et al. Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin. Eur. Urol. Oncol. 5, 84–91 (2022).

Article  PubMed  Google Scholar 

Guerrero-Ramos, F. et al. Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models. Bladder Cancer 8, 339–357 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Soukup, V. et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology non-muscle-invasive bladder cancer guidelines panel. Eur. Urol. Focus. 6, 479–489 (2020).

Article  PubMed  Google Scholar 

Jobczyk, M., Stawiski, K., Fendler, W. & Rozanski, W. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis. Cancer Med. 9, 4014–4025 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cordon-Cardo, C. et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84, 1251–1256 (1992).

Article  CAS  PubMed  Google Scholar 

Sarkis, A. S. et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst. 85, 53–59 (1993).

Article  CAS  PubMed  Google Scholar 

Casadevall, D., Kilian, A. Y. & Bellmunt, J. The prognostic role of epigenetic dysregulation in bladder cancer: a systematic review. Cancer Treat. Rev. 61, 82–93 (2017).

Article  CAS  PubMed  Google Scholar 

Birkenkamp-Demtroder, K. et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur. Urol. 70, 75–82 (2016).

Article  CAS  PubMed  Google Scholar 

De Carlo, C., Valeri, M., Corbitt, D. N., Cieri, M. & Colombo, P. Non-muscle invasive bladder cancer biomarkers beyond morphology. Front. Oncol. 12, 947446 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001).

Article  CAS  PubMed  Google Scholar 

Liu, J., Peng, Y. & Wei, W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 32, 30–44 (2022).

Article  CAS  PubMed  Google Scholar 

Hurst, C. D. et al. Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep. Med. 2, 100472 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitra, A. P., Birkhahn, M. & Cote, R. J. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25, 563–571 (2007).

Article  CAS  PubMed  Google Scholar 

Sjodahl, G. et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int. J. Cancer 146, 2636–2647 (2020).

Article  PubMed  Google Scholar 

Gatti, V., Fierro, C., Annicchiarico-Petruzzelli, M., Melino, G. & Peschiaroli, A. DeltaNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment. Mol. Oncol. 13, 981–1001 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152–165 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadimitriou, M. A. et al. DeltaNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. J. Cancer Res. Clin. Oncol. 145, 3075–3087 (2019).

Article  CAS  PubMed  Google Scholar 

Urist, M. J. et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 1199–1206 (2002).

Article  CAS  PubMed